Prior Immune Therapy Ups Lirafugratinib Side Effect Risk
Patients with prior immune checkpoint inhibitor exposure faced higher rates of mucocutaneous issues in a recent trial.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Do you trust that evolving research on drug side effects leads to safer medical treatments?
Data from the phase 1/2 ReFocus trial reveals that prior exposure to immune checkpoint inhibitors significantly increases the risk of dermatitis and mucositis in patients treated with the cancer drug lirafugratinib. Nearly all participants in the study developed some form of mucocutaneous adverse effect within three months of starting the treatment.
Why it matters
Understanding this elevated risk profile helps clinicians better manage treatment plans and potential dosage adjustments for cancer patients who have previously undergone immunotherapy. This insight is critical for optimizing patient safety as physicians navigate the complexities of using FGFR2 inhibitors in those with advanced solid tumors.
The study utilized 385 patients, showing an adjusted hazard ratio of 4.93 for dermatitis and 1.53 for mucositis among those with prior immunotherapy exposure. Lirafugratinib, which received FDA approval for cholangiocarcinoma on September 23, 2026, demonstrated a 46% objective response rate.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.
The details
Researchers utilized Fine-Gray subdistribution hazard ratios to analyze the trial data, identifying that prior immunotherapy exposure also correlated with a 1.73 adjusted hazard ratio for required dose reductions or interruptions. The trial, which included patients with a median age of 60, found that 60.3% of the study population suffered from cholangiocarcinoma.
Timeline
September 23, 2026: The FDA officially approved lirafugratinib for the treatment of cholangiocarcinoma.
October 23-27, 2026: The data was presented during the 2026 ESMO Congress held in Madrid.
October 29, 2026: The findings were formally published.
Health Landscape
The ReFocus trial provides a foundational data set for managing treatment-related toxicities in patients receiving targeted FGFR2 inhibition. These findings mark a departure from treating all patients with a uniform safety profile, instead highlighting how previous therapeutic interventions dictate current clinical risk.
Patients prescribed lirafugratinib who have a history of immunotherapy may experience more frequent dermatological or mucosal side effects that require medical intervention. It is essential for these individuals to discuss their prior treatment history with their oncology team to prepare for potential dose adjustments or proactive skin and oral care.
The takeaway
Patients starting new targeted therapies should ensure their complete treatment history is documented to help providers anticipate adverse effects. Proactive communication between the patient and medical team remains the best approach for managing drug-related toxicities.
Further reading
For more information on current treatment trends, visit the Cancer section.
More information
View the complete ReFocus trial study information for further clinical details.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust that evolving research on drug side effects leads to safer medical treatments?
